heat shock protein family E (Hsp10) member 1 pseudogene 22Genealiases: []
Q-omics provides the consensus-scored HSPE1P22 profile across patient tissues and cancer cell-line models. HSPE1P22 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, HSPE1P22 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, HSPE1P22 RNA expression shows 6,215 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, THCA, and STAD as cancer lineages where HSPE1P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPE1P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPE1P22 survival associations across molecular data types. HSPE1P22 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPE1P22 RNA expression–survival associations across cancer types. High HSPE1P22 expression shows unfavorable associations in THYM, BLCA, PRAD and LIHC, but favorable associations in LUSC and PAAD. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for HSPE1P22 RNA expression.
This table summarizes HSPE1P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSPE1P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPE1P22 shows lower tumor expression in THCA. The THCA box plot shows higher HSPE1P22 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .011).
This table shows molecular features associated with HSPE1P22 in patient tissues and cancer cell lines. In patient samples, HSPE1P22 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
